Report Tools

Generics in the Netherlands

Published: August 2013 · Publisher: MarketLine
Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017).
Report Type Industry Profiles
Language English
Format Electronic (PDF)
Pages34
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-6817
Price € 259,00
Options
  • Description
  • Companies Mentioned
  • Table of Contents
  • Ask a Question
Introduction

Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Netherlands generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

*The Dutch generics market had total revenues of $1.1bn in 2012, representing a compound annual growth rate (CAGR) of 3.1% between 2008 and 2012.

*Market consumption volume increased with a CAGR of 4.6% between 2008-2012, to reach a total of 67.2% of total pharma volume in 2012.

*The performance of the market is forecast to follow a similar pattern with an anticipated CAGR of 3.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $1.3bn by the end of 2017.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the Netherlands

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the Netherlands

Leading company profiles reveal details of key generics market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands generics market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the Netherlands economy

Key Questions Answered

What was the size of the Netherlands generics market by value in 2012?

What will be the size of the Netherlands generics market in 2017?

What factors are affecting the strength of competition in the Netherlands generics market?

How has the market performed over the last five years?

What are the main segments that make up the Netherlands's generics market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Bayer AG, ratiopharm Group, Sandoz International GmbH and Teva Pharmaceutical Industries Limited
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Bayer AG 20
ratiopharm Group 24
Sandoz International GmbH 25
Teva Pharmaceutical Industries Limited 26
Macroeconomic Indicators 30
Country Data 30
Appendix 32
Methodology 32
Industry associations 33
Related research 33

LIST OF TABLES
Table 1: Netherlands generics market value: $ million, 2008–12 9
Table 2: Netherlands generics market volume: % of total pharma volume, 2008–12 10
Table 3: Netherlands generics market geography segmentation: $ million, 2012 11
Table 4: Netherlands generics market value forecast: $ million, 2012–17 12
Table 5: Netherlands generics market volume forecast: % of total pharma volume, 2012–17 13
Table 6: Bayer AG: key facts 20
Table 7: Bayer AG: key financials ($) 21
Table 8: Bayer AG: key financials (€) 21
Table 9: Bayer AG: key financial ratios 22
Table 10: ratiopharm Group: key facts 24
Table 11: Sandoz International GmbH: key facts 25
Table 12: Teva Pharmaceutical Industries Limited: key facts 26
Table 13: Teva Pharmaceutical Industries Limited: key financials ($) 27
Table 14: Teva Pharmaceutical Industries Limited: key financial ratios 28
Table 15: Netherlands size of population (million), 2008–12 30
Table 16: Netherlands gdp (constant 2000 prices, $ billion), 2008–12 30
Table 17: Netherlands gdp (current prices, $ billion), 2008–12 30
Table 18: Netherlands inflation, 2008–12 31
Table 19: Netherlands consumer price index (absolute), 2008–12 31
Table 20: Netherlands exchange rate, 2008–12 31

LIST OF FIGURES
Figure 1: Netherlands generics market value: $ million, 2008–12 9
Figure 2: Netherlands generics market volume: % of total pharma volume, 2008–12 10
Figure 3: Netherlands generics market geography segmentation: % share, by value, 2012 11
Figure 4: Netherlands generics market value forecast: $ million, 2012–17 12
Figure 5: Netherlands generics market volume forecast: % of total pharma volume, 2012–17 13
Figure 6: Forces driving competition in the generics market in the Netherlands, 2012 14
Figure 7: Drivers of buyer power in the generics market in the Netherlands, 2012 15
Figure 8: Drivers of supplier power in the generics market in the Netherlands, 2012 16
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2012 17
Figure 10: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2012 18
Figure 11: Drivers of degree of rivalry in the generics market in the Netherlands, 2012 19
Figure 12: Bayer AG: revenues & profitability 22
Figure 13: Bayer AG: assets & liabilities 23
Figure 14: Teva Pharmaceutical Industries Limited: revenues & profitability 28
Figure 15: Teva Pharmaceutical Industries Limited: assets & liabilities 29
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.